Exploring Vaccination in Low-Grade Glioma With the Aim of Preventing High-Grade Transformation

Video

Hideho Okada, MD, PhD, director, Brain Tumor Immunotherapy Center, professor of Neurological Surgery, University of California, San Francisco, discusses a study exploring vaccination in low-grade glioma aiming at prevention of high-grade transformation.

Recent Videos
Related Content
Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Jordyn Sava
March 31st 2025
Article

Read More

Recommendations for Treating Central Nervous System Cancers

Recommendations for Treating Central Nervous System Cancers

Nichole Tucker;Craig Horbinski, MD, PhD
July 14th 2023
Podcast

In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.

Listen

VXM01 Plus Avelumab Shows Safety, Tolerability in Recurrent Glioblastoma

VXM01 Plus Avelumab Shows Safety, Tolerability in Recurrent Glioblastoma

Jordyn Sava
March 27th 2025
Article

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Read More

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More

Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma

Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma

Jordyn Sava
March 19th 2025
Article

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.

Read More